Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

200%(2 trials)

Terminated

2(67%)

Phase Distribution

Ph phase_1

33%

Ph phase_2

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (33.3%)

Phase 22 (66.7%)

Trials by Status

completed133%

terminated267%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_2

Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

NCT02265744

terminatedphase_2

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

NCT02843659

terminatedphase_1

Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

NCT03058822

Clinical Trials (3)

Showing 3 of 3 trials

NCT02265744Phase 2

Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

Completed

NCT02843659Phase 2

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Terminated

NCT03058822Phase 1

Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3